times up for antiviral stockpile, page-4

Yes, it is back to the good old "long standing relationship" with GSK again.
GSK had probably promoted Relenza very hard by sending potential clients a copy of GSK's court document praising Tamiflu and rubbishing Relenza!

Peter Cook and the BTA board steadfastly refused to settle for 2006 $100M, the best ever time to get on and sell Relenza; went on and burn in excess of $30M and then settle for $20M. This wonderful performance should justify the hundreds of thousands of free BTA shares issued to our wonderful management at zero exercise price days before they settle at $20M

Well done Peter Cook.